NASHnext: A Noninvasive Test for Identifying Risk of NASH Disease Progression

被引：0
|
作者：
Hoffman, Ariel [1 ]
Chandler, Molly [1 ]
机构：
[1] Madigan Army Med Ctr, Joint Base Lewis Mcchord, WA 98431 USA
来源：
AMERICAN FAMILY PHYSICIAN | 2023年 / 108卷 / 04期
关键词：
DIAGNOSIS;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：408 / 410
页数：3
相关论文
共 50 条
  • [21] Identifying informative risk factors and predicting bone disease progression via deep belief networks
    Li, Hui
    Li, Xiaoyi
    Ramanathan, Murali
    Zhang, Aidong
    METHODS, 2014, 69 (03) : 257 - 265
  • [22] Natural History of Nonalcoholic Hepatic Steatosis: Risk for Progression to NASH and Cirrhosis
    Hahn, L.
    Zelinski, N.
    Park, S.
    Pickhardt, P.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2012, 198 (05)
  • [23] ROUTINELY AVAILABLE NONINVASIVE TESTS PERFORM WELL IN IDENTIFYING PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: DATA FROM THE TARGET-NASH OBSERVATIONAL COHORT
    Barritt, Alfred Sidney
    Lok, Anna S.
    Reddy, K. Rajender
    Weiss, L. Michael
    Firpi, Roberto J.
    Thuluvath, Paul J.
    Trinh, Huy N.
    Djedjos, Stephen
    Haubrich, Richard
    Billin, Andrew
    Koch, Bruce, II
    Zink, Richard
    Sanyal, Arun J.
    Cusi, Kenneth
    Neuschwander-Tetri, Brent A.
    HEPATOLOGY, 2019, 70 : 1049A - 1049A
  • [24] RISK STRATIFICATION MODEL WITH A HIGH SENSITIVITY IN IDENTIFYING " AT- RISK" FIBROTIC NASH IN A SCREENING STUDY
    Tang, Dong
    Li, Hanyu
    Yang, Jun
    Nie, Kehui
    HEPATOLOGY, 2023, 78 : S872 - S872
  • [25] Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: Insight into risk stratification
    Ikeda, T
    Sakurada, H
    Sakabe, K
    Sakata, T
    Takami, M
    Noro, M
    Kawase, A
    Kumagai, K
    Tezuka, N
    Nakae, T
    Enjoji, Y
    Tejima, T
    Sugi, K
    Yamaguchi, T
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 134A - 134A
  • [26] Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: Insight into risk stratification
    Ikeda, T
    Sakurada, H
    Sakabe, K
    Sakata, T
    Takami, M
    Tezuka, N
    Nakae, T
    Noro, M
    Enjoji, Y
    Tejima, T
    Sugi, K
    Yamaguchi, T
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (06) : 1628 - 1634
  • [27] Identifying a subgroup of patients with asymptomatic myeloma who have a low risk of disease progression and long duration of stable disease
    Cannon, Philip
    Preston, Gavin
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 161 - 161
  • [28] Dysregulated sphingolipid metabolism contributes to NASH-HCC disease progression
    Zeng, Jing
    Zhao, Derrick
    Tai, Yun-ling
    Jiang, Xixian
    Su, Lianyong
    Wang, Xuan
    Gurley, Emily
    Hylemon, Phillip B.
    Fan, Jiangao
    Ase, Sayed Obaidullah
    Sanyal, Arun J.
    Zhou, Huiping
    PHYSIOLOGY, 2023, 38
  • [29] Microbiome & NASH - partners in crime driving progression of fatty liver disease
    Wree, Alexander
    Geisler, Lukas Jonathan
    Tacke, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (07): : 871 - 882
  • [30] Prospective validation of the Enhanced Liver Fibrosis (ELF) test for the prediction of disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis
    Harrison, Stephen A.
    Abdelmalek, Manal F.
    Diehl, Anna Mae
    Caldwell, Stephen
    Shiffman, Mitchell L.
    Ghalib, Reem
    Lawitz, Eric
    Rockey, Don C.
    Schall, Raul E. Aguilar
    Jia, Catherine
    McColgan, Bryan J.
    Myers, Robert P.
    Subramanian, Mani
    McHutchison, John G.
    Muir, Andrew J.
    Ratziu, Vlad
    Afdhal, Nezam H.
    Goodman, Zachary D.
    Bosch, Jaime
    Sanyal, Arun J.
    HEPATOLOGY, 2017, 66 : 1120A - 1121A
12345